Thrombotargets Europe S.L   Report issue

For profit Phase 3
Founded: Castelldefels Spain (2005)
Status: Defunct (2021)

Organization Overview

First Clinical Trial
2012
NCT01595360
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

Thrombotargets Europe

Active Ingredients

Drugs in Phase 3 Trials (1)

tt-173 (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Osteoarthritis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 1